11 April 2016 - SMC accepts three new medicines for routine use by NHS Scotland.

The SMC, which reviews newly licensed medicines, has today published advice accepting three new medicines for routine use by NHS Scotland.

Everolimus (Afinitor) for advanced breast cancer, isavuconazole (Cresemba) for invasive aspergillosis and mucormycosis (serious fungal infections) and camellia sinensis (Catephen) for genital and perianal warts were all accepted. The Committee was unable to accept ataluren (Translarna) for Duchenne muscular dystrophy and eculizumab (Soliris) for paroxysmal nocturnal haemoglobinuria, a rare genetic disease of the blood.

For more details, go to: http://www.scottishmedicines.org.uk/About_SMC/Latest_news/News_Articles/April_2016_decisions_news_release